Warren Huff | Chief Executive Officer |
Colin Meyer | Chief Research and Development Officer |
Manmeet Soni | Chief Operating and Chief Financial Officer |
Yigal Nochomovitz | Citi |
Sonya Bhatia | Goldman Sachs |
Carter Gould | Barclays |
Maury Raycroft | Jefferies |
Annabel Samimy | Stifel |
Brian Skorney | Baird |
Charles Duncan | Cantor Fitzgerald |
Matt Kaplan | Ladenburg Thalmann |
Ladies and gentlemen, thank you for standing by, and welcome to the Reata Pharmaceuticals’ Second Quarter 2021 Financial Results and Update on Development Programs Conference Call. An audio recording of today’s webcast will be available shortly after the call today in the Investors section of Reata’s website at reatapharma.com.
Before the company proceeds with its remarks, please note the forward-looking statements disclosure in the company’s press release. The company will be making forward-looking statements on today’s call. There are many factors that could cause results to differ from expectations, including those noted in the company’s SEC filings.